Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Equities researchers at SunTrust Banks issued their Q1 2018 EPS estimates for shares of Ekso Bionics Holdings in a research report issued on Wednesday. SunTrust Banks analyst B. Nudell anticipates that the company will earn ($0.07) per share for the quarter. SunTrust Banks also issued estimates for Ekso Bionics Holdings’ Q2 2018 earnings at ($0.09) EPS, Q3 2018 earnings at ($0.08) EPS and Q4 2018 earnings at ($0.10) EPS.
Ekso Bionics Holdings (NASDAQ:EKSO) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05). The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.40 million. Ekso Bionics Holdings had a negative return on equity of 323.00% and a negative net margin of 343.53%.
WARNING: “Equities Analysts Offer Predictions for Ekso Bionics Holdings, Inc.’s Q1 2018 Earnings (EKSO)” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2017/11/11/equities-analysts-offer-predictions-for-ekso-bionics-holdings-inc-s-q1-2018-earnings-ekso.html.
Separately, Zacks Investment Research downgraded Ekso Bionics Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th.
Shares of Ekso Bionics Holdings (NASDAQ EKSO) opened at $1.53 on Friday. Ekso Bionics Holdings has a 12 month low of $0.99 and a 12 month high of $4.90. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 2.04.
A number of institutional investors have recently modified their holdings of the stock. Intellectus Partners LLC raised its stake in Ekso Bionics Holdings by 5.3% during the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after buying an additional 5,294 shares during the period. Carl Domino Inc raised its stake in Ekso Bionics Holdings by 74.7% during the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after buying an additional 35,088 shares during the period. National Planning Corp raised its stake in shares of Ekso Bionics Holdings by 116.2% in the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after purchasing an additional 126,000 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Ekso Bionics Holdings by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after purchasing an additional 176,197 shares during the period. 2.62% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider Russ Angold sold 28,254 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $1.53, for a total transaction of $43,228.62. Following the sale, the insider now owns 250,678 shares of the company’s stock, valued at approximately $383,537.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have purchased 41,264 shares of company stock worth $48,255 and have sold 259,352 shares worth $399,373. Company insiders own 7.10% of the company’s stock.
About Ekso Bionics Holdings
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.